

Financial news for ALKS dated on 2020-05-27: Alkermes To Highlight New Data From Schizophrenia Portfolio At The American Society Of Clinical Psychopharmacology 2020 Annual Meeting

Financial news for ALKS dated on 2020-05-18: Shares of several healthcare companies are trading higher in sympathy with the overall market as optimism around a coronavirus vaccine increased following news from Moderna.

Financial news for ALKS dated on 2020-05-14: Alkermes To Present New Data From Schizophrenia Portfolio At SIRS Meeting

Financial news for ALKS dated on 2020-05-11: Alkermes Announces 'Expansion of Patient Services and Provider Network to Support Uninterrupted Access to ARISTADA and VIVITROL'

Financial news for ALKS dated on 2020-04-30: HC Wainwright & Co. Reiterates Neutral on Alkermes, Lowers Price Target to \$23

Financial news for ALKS dated on 2020-04-30: 108 Biggest Movers From Yesterday

Financial news for ALKS dated on 2020-04-29: Alkermes PLC shares are trading lower after the company reported Q1 earnings results.

Financial news for ALKS dated on 2020-04-29: Alkermes Q1 EPS \$0.010 Beats \$(0.060) Estimate, Sales \$246.220M Beat \$228.230M Estimate

Financial news for ALKS dated on 2020-04-29: The Daily Biotech Pulse: Inovio's MERS Vaccine Data, Fast Track Designation For Erytech, FDA Approves Higher Dose Of Merck's Keytruda

Financial news for ALKS dated on 2020-04-29: Alkermes: Q1 Earnings Insights

Financial news for ALKS dated on 2020-04-26: The Week Ahead In Biotech (April 26-May 2): Cancer Conference, Earnings News Flow In The Spotlight

Financial news for ALKS dated on 2020-04-23: 20 Healthcare Stocks Moving In Thursday's Pre-Market Session

Financial news for ALKS dated on 2020-04-17: Shares of several healthcare companies are trading higher amid optimistic coronavirus outlook following positive drug data from Gilead. This has raised hopes of a sooner return to spending and economic activity.

Financial news for ALKS dated on 2020-04-08: Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign.

Financial news for ALKS dated on 2020-04-02: Morgan Stanley Maintains Equal-Weight on Alkermes, Lowers Price Target to \$16

Financial news for ALKS dated on 2020-03-23: B of A Securities Maintains Neutral on Alkermes, Lowers Price Target to \$17

Financial news for ALKS dated on 2020-03-18: The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates

Financial news for ALKS dated on 2020-03-16: Shares of several healthcare companies are trading lower in sympathy with the overall market on continued downward momentum caused by the coronavirus. The virus has had a negative impact on the global economy.

Financial news for ALKS dated on 2020-03-12: Stocks That Hit 52-Week Lows On Thursday

Financial news for ALKS dated on 2020-03-12: The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO

Financial news for ALKS dated on 2020-03-11: The Daily Biotech Pulse: NY State Endorses Mallinckrodt's Opioid Settlement, Kamada To Work On COVID-19 Treatment

Financial news for ALKS dated on 2020-03-04: Journal of Clinical Psychiatry Publishes Data from Alkermes' Phase 3 ENLIGHTEN-1 Efficacy Study of ALKS 3831 in Patients With Schizophrenia

Financial news for ALKS dated on 2020-02-26: Shares of several healthcare and biotech companies are trading higher. Not seeing any news to justify the price action.

Financial news for ALKS dated on 2020-02-26: Shares of several healthcare and biotech companies are trading higher. Movement appears market related as equities have rebounded this session following recent selloffs.

Financial news for ALKS dated on 2020-02-20: Alkermes shares are trading higher. Not seeing any news to justify the price action.

Financial news for ALKS dated on 2020-02-14: Stocks That Hit 52-Week Lows On Friday

Financial news for ALKS dated on 2020-02-14: Alkermes PLC shares are trading lower after the company issued FY20 EPS and sales guidance on the lower end of analyst estimates.

Financial news for ALKS dated on 2020-02-14: H.C. Wainwright Maintains Neutral on Alkermes, Lowers Price Target to \$25

Financial news for ALKS dated on 2020-02-14: JP Morgan Downgrades Alkermes to Neutral, Lowers Price Target to \$21

Financial news for ALKS dated on 2020-02-13: Alkermes PLC shares are trading lower after the company issued FY20 EPS and sales guidance on the lower end of analyst estimates.

Financial news for ALKS dated on 2020-02-13: The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO

Financial news for ALKS dated on 2020-02-13: Alkermes Sees FY20 Sales \$1.03B-\$1.08B vs \$1.06B Estimate

Financial news for ALKS dated on 2020-02-13: Alkermes Sees FY20 Adj. EPS \$0.25-\$0.44 vs \$0.44 Estimate

Financial news for ALKS dated on 2020-02-13: Alkermes Q4 EPS \$0.83 Beats \$0.65 Estimate, Sales \$412.7M Beat \$404.5M Estimate

Financial news for ALKS dated on 2020-02-09: The Week Ahead In Biotech: SMID-Cap Earnings In The Spotlight

Financial news for ALKS dated on 2020-02-06: Mizuho Initiates Coverage On Alkermes with Neutral Rating, Announces \$19 Price Target

Financial news for ALKS dated on 2020-02-05: Mizuho Initiates AbbVie, Biohaven With Buy Ratings, Eli Lilly, Alkermes With Neutral Ratings

Financial news for ALKS dated on 2020-02-05: Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.

Financial news for ALKS dated on 2020-02-04: The Daily Biotech Pulse: EyePoint In-Licenses Eye Disorder Drug, BioMarin CFO Quits, Rockwell Medical To Offer Shares

Financial news for ALKS dated on 2020-01-28: The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics

Financial news for ALKS dated on 2020-01-28: Alkermes Announces FDA Acceptance Of ALKS 3831 New Drug Application For Treatment Of Schizophrenia And Bipolar I Disorder

Financial news for ALKS dated on 2020-01-17: Alkermes Option Alert: Feb 21 \$18 Puts at the Bid: 2607 @ \$0.5 vs 13 OI; Earnings 2/13 Before Open [est] Ref=\$19.465

Financial news for ALKS dated on 2019-12-11: UPDATE: FDA Says Alkermes' Vivitrol Ad Use Is False/Misleading, Omits Important Risk Info

Financial news for ALKS dated on 2019-12-11: FDA's Office Of Prescription Drug Promotion Reviewed Print Ad By Alkermes For Vivitrol

Financial news for ALKS dated on 2019-12-02: Shares of several healthcare stocks are trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.

Financial news for ALKS dated on 2019-11-19: Alkermes Submits New Drug Application To FDA For ALKS 3831 For Treatment Of Schizophrenia And Bipolar I Disorder

Financial news for ALKS dated on 2019-11-18: Alkermes PLC shares are trading lower after the company announced it would acquire Rodin Therapeutics for \$100 million in cash.

Financial news for ALKS dated on 2019-11-18: Alkermes to Acquires Rodin Therapeutics for \$100M Cash

Financial news for ALKS dated on 2019-11-12: Alkermes Receives \$150M Milestone Payment From Biogen Related To FDA Approval Of VUMERITY

Financial news for ALKS dated on 2019-11-08: The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

Financial news for ALKS dated on 2019-11-07: Biotech Stock On The Radar: Alkermes At A Crossroads

Financial news for ALKS dated on 2019-11-03: The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight

Financial news for ALKS dated on 2019-10-30: Biogen And Alkermes Announce FDA Approval Of VUMERITY (diroximel fumarate) For Multiple Sclerosis

Financial news for ALKS dated on 2019-10-24: Alkermes shares are trading higher on continued strength after the company on Wednesday reported strong Q3 results.

Financial news for ALKS dated on 2019-10-23: Alkermes PLC shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.

Financial news for ALKS dated on 2019-10-23: 33 Healthcare Stocks Moving In Wednesday's Pre-Market Session

Financial news for ALKS dated on 2019-10-23: The Daily Biotech Pulse: Eli Lilly Revenues Trail Estimates, Moderna Gets Fast Track Designation, MacroGenics' Lukewarm Breast Cancer Data

Financial news for ALKS dated on 2019-10-23: Alkermes Sees \$150M In Cost Savings From Restructuring

Financial news for ALKS dated on 2019-10-23: Alkermes Sees FY19Adj. EPS \$0.44-\$0.57, Sakes \$1.14B-\$1.19B

Financial news for ALKS dated on 2019-10-23: Alkermes Q3 Adj. EPS \$(0.04) Beats \$(0.21) Estimate, Sales \$255.2M Beat \$251.16M Estimate

Financial news for ALKS dated on 2019-10-21: Alkermes to Collaborate with Fred Hutchinson Cancer Research Center on Immuno-Oncology Drug Candidate ALKS 4230

Financial news for ALKS dated on 2019-10-11: The Daily Biotech Pulse: Therapix Extends Merger Deadline, Five Prime Restructures, Gilead-Galapagos Rheumatism Drug Readout

Financial news for ALKS dated on 2019-10-10: Alkermes shares are trading lower despite no company-specific news. The stock has dropped approximately 26% over the last month.

Financial news for ALKS dated on 2019-10-08: Stocks That Hit 52-Week Lows On Tuesday

Financial news for ALKS dated on 2019-10-02: Stocks That Hit 52-Week Lows On Wednesday

Financial news for ALKS dated on 2019-10-02: The Daily Biotech Pulse: J&J Settles Ohio Opioid Lawsuit, Teligent Explores Options For Certain Assets, Novartis Reports Cosentyx Data

Financial news for ALKS dated on 2019-10-01: Stocks That Hit 52-Week Lows On Tuesday

Financial news for ALKS dated on 2019-10-01: Shares of several healthcare stocks are trading lower in sympathy with the overall market after the Institute for Supply Management said U.S. manufacturing activity shrunk to its lowest level since June 2009, adding fears of an economic slowdown.

Financial news for ALKS dated on 2019-10-01: The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines

Financial news for ALKS dated on 2019-09-30: Stocks That Hit 52-Week Lows On Monday

Financial news for ALKS dated on 2019-09-24: Alkermes shares are trading lower after the stock could not stay above the \$21 support level. NOTE: An overnight filing showed that the company's CEO exercised an option for 100,000 shares and sold at \$21.5355 per share as part of his compensation. This does not normally cause the stock to trade lower.

Financial news for ALKS dated on 2019-09-17: Alkermes shares trading lower as stock pulls back from \$23 resistance level. The stock rallied 12% over Tuesday and Wednesday of last week to push over the \$21 level. Did not see news to justify the recent moves.

Financial news for ALKS dated on 2019-09-05: UPDATE: Morgan Stanley On Alkermes Also Notes 'We see long-term risk to royalty streams balanced by pipeline or cost savings optionality'

Financial news for ALKS dated on 2019-09-05: UPDATE: Morgan Stanley Upgrades Alkermes To Equal-Weight, Lowers Target To \$20 As Firm Notes 'Shares have underperformed, and recent developments eliminated the worst-case scenarios for Vumerity trial results and Vivitrol's patent'

Financial news for ALKS dated on 2019-09-05: Benzinga's Top Upgrades, Downgrades For September 5, 2019

Financial news for ALKS dated on 2019-09-05: Morgan Stanley Upgrades Alkermes to Equal-Weight, Lowers Price Target from \$30 to \$20

Financial news for ALKS dated on 2019-08-26: Stocks That Hit 52-Week Lows On Monday

Financial news for ALKS dated on 2019-08-19: Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.

Financial news for ALKS dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for ALKS dated on 2019-08-13: Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.

Financial news for ALKS dated on 2019-08-03: The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts

Financial news for ALKS dated on 2019-07-30: Alkermes PLC shares are trading higher after the company reported that the Diroximel Fumarate demonstrated statistically Superior Gastrointestinal Tolerability for the company's EVOLVE-MS-2 primary endpoint.

Financial news for ALKS dated on 2019-07-30: Alkermes, Biogen Report Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported GI Events

Financial news for ALKS dated on 2019-07-29: Alkermes Enters Into A Settlement And License Agreement With Amneal Pharmaceuticals To Resolve Amneal's Inter Partes Review Petition Challenging U.S. Patent Number 7,919,499, For Vivitrol That Expires In 2029

Financial news for ALKS dated on 2019-07-27: The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate

Financial news for ALKS dated on 2019-07-26: Stocks That Managed to Breach 52-Week Lows Friday

Financial news for ALKS dated on 2019-07-26: The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint

Financial news for ALKS dated on 2019-07-25: Alkermes shares are trading lower after the company reported Q2 earnings results.

Financial news for ALKS dated on 2019-07-25: The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug

Financial news for ALKS dated on 2019-07-25: Alkermes Q2 EPS \$0.09 Beats \$(0.12) Estimate, Sales \$279.872M Beat \$251.39M Estimate

Financial news for ALKS dated on 2019-07-15: Benzinga's Top Upgrades, Downgrades For July 15, 2019

Financial news for ALKS dated on 2019-07-15: Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder

Financial news for ALKS dated on 2019-07-15: Goldman Sachs Upgrades Alkermes to Neutral, Announces \$27 Price Target

Financial news for ALKS dated on 2019-07-08: Shares of several healthcare companies are trading lower after Trump on Friday said he was preparing an executive order declaring a 'favored nations clause' for drug prices, lowering the price that consumers will pay prescription drugs.

Financial news for ALKS dated on 2019-06-12: Alkermes Initiates Monotherapy Expansion Phase Of ARTISTRY-1 In Patients With Renal Cell Carcinoma Or Melanoma

Financial news for ALKS dated on 2019-06-04: Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.

Financial news for ALKS dated on 2019-05-31: H.C. Wainwright Initiates Coverage On Alkermes with Neutral Rating, Announces \$28 Price Target

Financial news for ALKS dated on 2019-05-31: The Daily Biotech Pulse: Merrimack To Stay Independent, Chinese Cheer For Beigene, XBiotech Offering

Financial news for ALKS dated on 2019-05-30: The Daily Biotech Pulse: Unity Biotech Licenses Anti-Aging Protein, Strong Results For Mereo's Brittle Bone Disease Drug

Financial news for ALKS dated on 2019-05-29: The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation

Financial news for ALKS dated on 2019-05-24: The Daily Biotech Pulse: FDA Nod For Novocure, Dynavax Restructures, Therapix Receives Nasdaq Notice

Financial news for ALKS dated on 2019-05-22: Alkermes Reports Will Present New Data From Mental Health Portfolio At American Society of Clinical Psychopharmacology 2019 Annual Meeting

Financial news for ALKS dated on 2019-05-21: The Daily Biotech Pulse: Setback For Merck In Breast Cancer Study, Arrowhead to Join S&P SmallCap 600 Index, Ocular's Glaucoma Trial Fails

Financial news for ALKS dated on 2019-05-14: The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings

Financial news for ALKS dated on 2019-05-10: The Daily Biotech Pulse: FibroGen Kidney Disease Trial Disappoints, Medtronic To Buy Titan Spine, Puma's Weak Breast Cancer Drug Sales

Financial news for ALKS dated on 2019-05-01: 10 Biggest Price Target Changes For Wednesday

Financial news for ALKS dated on 2019-05-01: Citigroup Downgrades Alkermes plc - Ordinary Shares to Neutral, Lowers Price Target to \$33

Financial news for ALKS dated on 2019-04-30: Shares of several healthcare companies are trading lower on continued uncertainty over healthcare policy as well as concerns over the medicare-for-all proposals among 2020 candidates.

Financial news for ALKS dated on 2019-04-26: 55 Biggest Movers From Yesterday

Financial news for ALKS dated on 2019-04-25: Alkermes shares trading lower despite reporting better-than-expected Q1 results.

Financial news for ALKS dated on 2019-04-25: The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

Financial news for ALKS dated on 2019-04-25: Alkermes Q1 Adj. EPS \$(0.17) Beats \$(0.22) Estimate, Sales \$223.102M Beat \$216.99M Estimate

Financial news for ALKS dated on 2019-04-11: The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug

Financial news for ALKS dated on 2019-04-09: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ALKS dated on 2019-04-09: Alkermes' ARISTADA Met its Primary Endpoint

Financial news for ALKS dated on 2019-04-08: Alkermes Reports Pres, COO Jim Robinson To Leave Co.

Financial news for ALKS dated on 2019-04-07: The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trial Readouts

Financial news for ALKS dated on 2019-04-01: Alkermes, Merck, Sage Therapeutics and Takeda Pharma Announce a Partnership to Qualify Biomarkers for Schizophrenia Drug Development

Financial news for ALKS dated on 2019-02-26: Alkermes Reports Initiation Of Clinical Study Of ALKS 4230 Administered Subcutaneously In Patients With Advanced Solid Tumors

Financial news for ALKS dated on 2019-02-25: Alkermes and Biogen Announce U.S. Food and Drug Administration Acceptance of Diroximel Fumarate New Drug Application for Multiple Sclerosis

Financial news for ALKS dated on 2019-02-19: Alkermes And Clovis Oncology Initiate Research Collaboration To Explore Combination Cancer Therapies

Financial news for ALKS dated on 2019-02-14: The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial

Financial news for ALKS dated on 2019-02-14: Alkermes Sees FY19 Sales Of Proprietary Products Up ~24% Year Over Year

Financial news for ALKS dated on 2019-02-14: Alkermes Q4 EPS \$0.34 Up From \$0.31 YoY, Sales \$315.8M Beat \$255.09M Estimate

Financial news for ALKS dated on 2019-02-01: Alkermes Receives Complete Response Letter From FDA For ALKS 5461 New Drug Application; FDA Said It Is Unable To Approve Drug In Its Current Form And Is Requesting Additional Clinical Data

Financial news for ALKS dated on 2019-01-31: The Daily Biotech Pulse: Hologic, Celgene Earnings, FDA To Rule On Alkermes Depression Drug

Financial news for ALKS dated on 2019-01-29: Allakos Announces Phase 2 Results Of AK002 In Patients With Cholinergic Urticaria And Symptomatic Dermographism; Results Show 82% Response Rate In Cholinergic Urticaria Patients, 70% In Symptomatic Dermographism Patients

Financial news for ALKS dated on 2019-01-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

Financial news for ALKS dated on 2018-12-31: Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Financial news for ALKS dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for ALKS dated on 2018-12-20: The Daily Biotech Pulse: Tilray Inks Cannabis Drink Pact, Double Delight For Merck, FDA Snub For Spectrum

Financial news for ALKS dated on 2018-12-19: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 18, 2018

Financial news for ALKS dated on 2018-12-19: UPDATE: Goldman Sachs Downgrades Alkermes As Recent Checks Show 'the current profile of ALKS-3831 for schizophrenia based on weight gain alone suggests that the drug is unlikely to be practice changing'

Financial news for ALKS dated on 2018-12-19: 10 Biggest Price Target Changes For Wednesday

Financial news for ALKS dated on 2018-12-19: Alkermes Catches A 'Sell' Downgrade On Depression Therapy, M&A Prospects

Financial news for ALKS dated on 2018-12-19: Benzinga's Top Upgrades, Downgrades For December 19, 2018

Financial news for ALKS dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for ALKS dated on 2018-12-19: Goldman Sachs Downgrades Alkermes to Sell, Lowers Price Target to \$26

Financial news for ALKS dated on 2018-12-18: Alkermes Shares Indicated Down 5-6% After Hours On Light Volume; Hearing Goldman Issued Post-Market Downgrade To Sell

Financial news for ALKS dated on 2018-12-17: Alkermes And Biogen Announce Submission Of New Drug Application To U.S. Food And Drug Administration For Diroximel Fumarate In Multiple Sclerosis

Financial news for ALKS dated on 2018-12-13: 36 Stocks Moving In Thursday's Mid-Day

Session

Financial news for ALKS dated on 2018-12-13: Alkermes shares are trading lower after Credit Suisse lowered its rating on the stock from outperform to underperform and lowered its price target from \$47 to \$31.

Financial news for ALKS dated on 2018-12-13: Credit Suisse Downgrades Alkermes to Underperform, Lowers Price Target to \$31

Financial news for ALKS dated on 2018-11-30: What's Going On With Adial Pharmaceuticals?

Financial news for ALKS dated on 2018-11-29: Alkermes Shares Resume Trade

Financial news for ALKS dated on 2018-11-29: Alkermes Shares To Resume Trade At 7:30 a.m. EST

Financial news for ALKS dated on 2018-11-29: Alkermes Says Plans To Submit New Drug Application For ALKS 3831 In Mid 2019

Financial news for ALKS dated on 2018-11-29: Alkermes Reports ALKS 3831 Trial Met Both Co-Primary Endpoints

Financial news for ALKS dated on 2018-11-29: Alkermes Shares Halted News Pending

Financial news for ALKS dated on 2018-11-15: Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 14, 2018

Financial news for ALKS dated on 2018-11-15: Leerink Swann Initiates Coverage On Alkermes with Market Perform Rating, Announces \$36 Price Target

Financial news for ALKS dated on 2018-11-15: The Daily Biotech Pulse: FDA Nod For Mallinckrodt's Pain Drug, AbbVie-Neurocrine Report Positive Elagolix Results

Financial news for ALKS dated on 2018-11-14: The Daily Biotech Pulse: Mallinckrodt Faces FDA Panel, Reshape's Earnings, Vapotherm To Debut

Financial news for ALKS dated on 2018-11-13: Leerink Swann Initiates Coverage On Alkermes with Market Perform Rating, Announces \$36 Price Target

Financial news for ALKS dated on 2018-11-13: The Daily Biotech Pulse: Viking's Fatty Liver And Cholesterol Drug, Cyclacel Loss Narrows, Eton's Debut

Financial news for ALKS dated on 2018-11-12: Morgan Stanley On Alkermes: Reiterates Underweight As They Expect Disappointing Data On ALKS 3831

Financial news for ALKS dated on 2018-11-09: The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall

Financial news for ALKS dated on 2018-11-06: Alkermes To Present New Data On ALKS 4230 At Society For Immunotherapy Of Cancer's (SITC) 33rd Annual Meeting

Financial news for ALKS dated on 2018-11-05: Benzinga's Top Upgrades, Downgrades For November 5, 2018

Financial news for ALKS dated on 2018-11-05: PiperJaffray Initiates Coverage On Alkermes with Neutral Rating, Announces \$40 Price Target

Financial news for ALKS dated on 2018-11-02: FDA Committees' Unfavorable Ruling Depresses Alkermes Shares

Financial news for ALKS dated on 2018-11-02: The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug

Financial news for ALKS dated on 2018-11-02: Alkermes Says 'Disappointed and Surprised' by FDA Advisory Committee Negative Vote on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder

Financial news for ALKS dated on 2018-11-01: Alkermes Shares To Resume Trade At 6:45 p.m. EDT

Financial news for ALKS dated on 2018-11-01: 'Ad comm votes 2-21 that the available data do NOT support a favorable benefit-risk profile of \$ALKS' buprenorphine/samidorphane to support approval' -Tweet From Pharma Pink Sheet Reporter Michael Cipriano On Alkermes AdCom

Financial news for ALKS dated on 2018-11-01: 'Vote tally is Yes: 3, No: 20.' -CNBC's Meg Tirrell Tweets On Alkermes AdCom Panel Vote For ALKS 5461

Financial news for ALKS dated on 2018-11-01: Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates

Financial news for ALKS dated on 2018-11-01: The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal

Financial news for ALKS dated on 2018-11-01: UPDATE: Alkermes Shares Halted Ahead of FDA Panel

Financial news for ALKS dated on 2018-11-01: Alkermes Shares Halted News Pending

Financial news for ALKS dated on 2018-11-01: REMINDER: Alkermes Has FDA AdCom Meeting for ALKS 5461 Today; Despite Refusal to File Letter On 4/2/18 Co. Announced Its NDA Was Accepted 4/16/18

Financial news for ALKS dated on 2018-10-30: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ALKS dated on 2018-10-30: 'FDA briefing documents for \$ALKS '5461 panel are live' -Tweet From STAT News' Adam Feuerstein

Financial news for ALKS dated on 2018-10-29: Alkermes Issues Press Release Highlighting Publication Of Previously-Disclosed Phase 3 Data For ALKS 5461 For Adjunctive Treatment of Major Depressive Disorder; BZ NOTE: Advisory Committee Panel Meeting For ALKS 5461 Is Scheduled Thurs., Nov. 1, 2018

Financial news for ALKS dated on 2018-10-29: Benzinga's Week Ahead: Can Facebook, Apple Earnings Rescue The Stock Market?

Financial news for ALKS dated on 2018-10-27: The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Financial news for ALKS dated on 2018-10-24: Stocks Which Set New 52-Week Low Yesterday, October 23rd

Financial news for ALKS dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for ALKS dated on 2018-10-23: The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

Financial news for ALKS dated on 2018-10-23: UPDATE: Alkermes Raises FY18 Sales Guidance From \$975M-\$1.025B To \$1.015B-\$1.045B vs \$1.02B Estimate, Sees Adj. EPS \$0.12-\$0.31 vs \$0.07 Est.

Financial news for ALKS dated on 2018-10-23: Alkermes Raises Guidance

Financial news for ALKS dated on 2018-10-23: Alkermes plc Q3 EPS \$0.07 Beats \$(0.07) Estimate, Sales \$248.72M Beat \$237.26M Estimate

Financial news for ALKS dated on 2018-10-22: Alkermes Q3 Earnings Preview

Financial news for ALKS dated on 2018-10-21: The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs

Financial news for ALKS dated on 2018-09-18: Stocks Which Set New 52-Week Low Yesterday, September 17th

Financial news for ALKS dated on 2018-09-18: The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares

Financial news for ALKS dated on 2018-09-17: Stocks Which Set New 52-Week Low Friday, September 14

Financial news for ALKS dated on 2018-09-10: Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab

Financial news for ALKS dated on 2018-08-24: Oklahoma Healthcare Authority Says Medicaid Program Signs First 'Value-Based' Contract For Alkermes Antipsychotic Drug, Says Two Similar Prescription Deals Are In The Works

Financial news for ALKS dated on 2018-08-07: Benzinga's Top Upgrades, Downgrades For August 7, 2018

Financial news for ALKS dated on 2018-08-07: Stifel Nicolaus Initiates Coverage On Alkermes with Hold Rating, Announces \$45 Price Target

Financial news for ALKS dated on 2018-07-26: Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold

Financial news for ALKS dated on 2018-07-26: Alkermes Reaffirms FY18 Outlook

Financial news for ALKS dated on 2018-07-26: Alkermes Q2 EPS \$0.29 Beats \$0.14 Estimate, Sales \$304.642M Beat \$247.08M Estimate

Financial news for ALKS dated on 2018-07-25: Earnings Preview: Alkermes

Financial news for ALKS dated on 2018-07-25: UPDATE: Acorda, Alkermes v. Roxane Labs, Mylan, Teva Doc Shows 'On July 23, 2018, Acorda notified the court that "Acorda plans to seek an emergency injunction on July 25, 2018 absent a change in circumstances."'

Financial news for ALKS dated on 2018-07-25: Hearing Acorda Loses Bid For Emergency Order Blocking Ampyra Copy, Co. Is Awaiting Decision On Validity Of Ampyra Patents

Financial news for ALKS dated on 2018-07-16: UPDATE: Alkermes Veterans Affair Contract For 'Single source innovator, multiple source innovator, biological & insulin pharmaceutical products'

Financial news for ALKS dated on 2018-07-16: Alkermes Shares Spike To Session High Over \$45, Up 1.7% For Session; Traders Circulate FedBizOpps.gov Alert Co. Awarded Dept. Of Veterans Affairs Contract For ~\$186M

Financial news for ALKS dated on 2018-07-14: Analyst: Opioid Legislation Likely Stalled In Senate Until After November Elections

Financial news for ALKS dated on 2018-07-05: A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year

Financial news for ALKS dated on 2018-07-02: Benzinga Pro's 5 Stocks To Watch Today

Financial news for ALKS dated on 2018-07-02: Alkermes' ARISTADAD INITIO is Approved by the FDA for the Initiation of ARISTADA for Schizophrenia

Financial news for ALKS dated on 2018-06-29: REMINDER: Alkermes Has PDUFA Date for ARISTADA June 30th

Financial news for ALKS dated on 2018-06-29: Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos

Financial news for ALKS dated on 2018-06-28: Benzinga's Daily Biotech Pulse: Eli Lilly, Edge Therapeutics, BioXcel Report Positive Trial Results, 4 Stocks Debut

Financial news for ALKS dated on 2018-06-24: The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

Financial news for ALKS dated on 2018-06-22: 56 Biggest Movers From Yesterday

Financial news for ALKS dated on 2018-06-21: Alkermes PLC Shares Down 13.3% After Morgan Stanley Earlier Downgraded Stock From Equal-Weight To Underweight And Lowered Price Target From \$67 To \$42

Financial news for ALKS dated on 2018-06-21: 44 Stocks Moving In Thursday's Mid-Day Session

Financial news for ALKS dated on 2018-06-21: Benzinga's Top Upgrades, Downgrades For June 21, 2018

Financial news for ALKS dated on 2018-06-21: Morgan Stanley Downgrades Alkermes to Underweight, Lowers Price Target to \$42

Financial news for ALKS dated on 2018-06-06: Benzinga's Top Upgrades, Downgrades For June 6, 2018

Financial news for ALKS dated on 2018-06-06: Benzinga Pro's 5 Stocks To Watch Today

Financial news for ALKS dated on 2018-06-06: B. Riley FBR Initiates Coverage On Alkermes with Buy Rating, Announces \$60 Price Target

Financial news for ALKS dated on 2018-06-06: UPDATE: Alkermes Says May Also Receive \$150M Milestone Payment From Biogen Upon FDA Approval Of NDA For BIIB098

Financial news for ALKS dated on 2018-06-06: Alkermes Reports Received \$50M Payment From Biogen Related To Review Of Prelim. Gastrointestinal Tolerability Data From Ongoing BIIB098 Development Program

Financial news for ALKS dated on 2018-05-16: Citigroup Upgrades Alkermes to Buy

Financial news for ALKS dated on 2018-05-11: Bank of America Initiates Coverage On Alkermes with Buy Rating, Announces \$56 Price Target

Financial news for ALKS dated on 2018-04-26: Benzinga's Daily Biotech Pulse: Catabasis Soars On Trial Results, Eloxx Listing, Biomarin Earnings

Financial news for ALKS dated on 2018-04-26: Alkermes Q1 Adj. EPS \$(0.09) Misses \$(0.07) Est., Sales \$225.2M Beats \$219M Est.

Financial news for ALKS dated on 2018-04-17: 38 Biggest Movers From Yesterday

Financial news for ALKS dated on 2018-04-16: 31 Stocks Moving In Monday's Mid-Day Session

Financial news for ALKS dated on 2018-04-16: Mid-Day Market Update: Crude Oil Down Over 1%; Eldorado Resorts Shares Surge

Financial news for ALKS dated on 2018-04-16: Mid-Morning Market Update: Markets Open Higher; Bank of America Earnings Top Estimates

Financial news for ALKS dated on 2018-04-16: 23 Stocks Moving In Monday's Pre-Market Session

Financial news for ALKS dated on 2018-04-16: Alkermes Reports FDA Acceptance For Review NDA For ALKS 5461 For Adjunctive Treatment Of Major Depressive Disorder

Financial news for ALKS dated on 2018-04-03: 41 Biggest Movers From Yesterday

Financial news for ALKS dated on 2018-04-02: Mid-Afternoon Market Update: Dow Falls Over 500 Points; Crude Oil Down 2.5%

Financial news for ALKS dated on 2018-04-02: 33 Stocks Moving In Monday's Mid-Day Session

Financial news for ALKS dated on 2018-04-02: 'Talking \$ALKS FDA decision and implications for other biotechs, coming up on @HalftimeReport'

Financial news for ALKS dated on 2018-04-02: Mid-Day Market Update: NASDAQ Down Over 2%; SELLAS Life Sciences Shares Spike Higher

Financial news for ALKS dated on 2018-04-02: Alkermes Shares Fall To Session Lows; Hearing Evercore ISI Issued Mid-Day Downgrade On Issue

Financial news for ALKS dated on 2018-04-02: Benzinga Pro's Most-Searches Tickers For Mon., Apr. 2, 2018

Financial news for ALKS dated on 2018-04-02: Mid-Morning Market Update: Markets Open Lower; Cal-Maine Foods Posts Upbeat Sales

Financial news for ALKS dated on 2018-04-02: Alkermes CEO, Asked About FDA's Decision On Co.'s Depression Drug On Conf. Call, Says 'We don't believe any additional clinical trials are necessary'

Financial news for ALKS dated on 2018-04-02: Alkermes Falls 20% After FDA Refusal To File Letter

Financial news for ALKS dated on 2018-04-02: 28 Stocks Moving In Monday's Pre-Market Session

Financial news for ALKS dated on 2018-04-02: Alkermes Receives Refusal to File Letter From FDA for ALKS 5461, Alkermes to Provide Updated Guidance

Financial news for ALKS dated on 2018-04-02: Adam F Tweet: \$ALKS -- '5461 RTF letter is a big setback. Richard Pops assured investors this drug was getting approved, despite all the conflicting clinical data.

Financial news for ALKS dated on 2018-04-02: Alkermes Halted, News Pending

Financial news for ALKS dated on 2018-03-01: Alkermes Appoints James Robinson as President and COO

Financial news for ALKS dated on 2018-02-22: Benzinga's Top Upgrades, Downgrades For February 22, 2018

Financial news for ALKS dated on 2018-02-22: The Market In 5 Minutes: Jobless Claims Fall, 10-Year Treasury Yields, Twitter Makes Some Changes

Financial news for ALKS dated on 2018-02-22: Jefferies Downgrades Alkermes to Hold

Financial news for ALKS dated on 2018-02-14: Alkermes Sees FY18 Sales \$975-\$1.025B vs \$999M Est., EPS \$(0.23)-\$(0.03)

Financial news for ALKS dated on 2018-02-14: Alkermes Reports Q4 EPS \$0.33 vs \$0.23 Est., Sales \$275M vs \$252M Est.

Financial news for ALKS dated on 2018-02-02: Shares of Alkermes Trade Higher Following Chatter That Nektar Therapeutics Has Takeover Interest from Larger Drug Makers, Alkermes' Products Have Similarities to Nektar

Financial news for ALKS dated on 2018-01-31: Alkermes Reports Submission Of NDA For ALKS 5461 For Adjunctive Treatment Of Major Depressive Disorder

Financial news for ALKS dated on 2018-01-09: JP Morgan Healthcare Conference Continues Today, Presenters Include: Bluebird Bio, Agilent, Insulet, Cigna, DexCom, Eli Lilly, LifePoint, Acadia, Alkermes, Juno Therapeutics

Financial news for ALKS dated on 2017-12-05: PRIMECAP Management Reports 11.35% Stake In Alkermes

Financial news for ALKS dated on 2017-11-30: Senior S&P Global News Reporter Donna Young Tweets '@andrewkolodny says he has serious concerns about \$ALKS Vivitrol being used in wrong patients. We don't have good data on best med for right patient...'

Financial news for ALKS dated on 2017-11-28: Alkermes Wins '061 Patent Trial Over Lyue Pharma As Multi-Drug Patent Claims Upheld As Valid

Financial news for ALKS dated on 2017-11-27: Biogen and Alkermes Announce License and Collaboration Agreement to Develop and Commercialize ALKS 8700 for the Treatment of Multiple Sclerosis, Plans to Submit NDA in 2018

Financial news for ALKS dated on 2017-11-16: UPDATE: Alkermes Highlights FDA Action For Aripiprazole Lauroxil NanoCrystal(r) Dispersion Jun. 30, 2018

Financial news for ALKS dated on 2017-11-16: Alkermes Reports NDA For 'Initiation With Aripiprazole Lauroxil NanoCrystal Dispersion(r) Designed to Replace Need for Concomitant Three Weeks of Oral Aripiprazole With First ARISTADA Dose'

Financial news for ALKS dated on 2017-11-15: Alkermes Tues. Afternoon Highlighted VIVITROL, Value Of Medication-Assisted Treatment Of Opioid Dependence Featured In Study Sponsored By National Institute On Drug Abuse

Financial news for ALKS dated on 2017-11-15: Jefferies 2107 London Healthcare Conference Begins Today, Presenters Include: Alkermes, Bristol-Myers, Immunogen, and Eagle Pharmaceuticals

Financial news for ALKS dated on 2017-11-08: Alkermes Reports Preclinical Data For ALKS 4230 Showed 'Preferential Expansion and Tumor Infiltration of Select Tumor-Killing Immune Cells in Preclinical Xenograft Model of Metastatic Melanoma'

Financial news for ALKS dated on 2017-11-06: Adam Feuerstein Tweets: I get why Kamala Harris piling on \$ALKS for Vivitrol marketing is newsworthy but it's also nonsensical political grandstanding at its worst.

Financial news for ALKS dated on 2017-11-06: Senator Harris Releases Statement Launching Investigation Into Alkermes Regarding Opioid Addiction Treatment Manipulation

Financial news for ALKS dated on 2017-11-06: Alkermes Shares Plunge To Session Lows As Traders Circulate Word Senator Harris Has Launched Probe Into Co.'s Vivitrol

Financial news for ALKS dated on 2017-10-26: Alkermes Sees FY17 Adj. EPS \$(0.10)-\$0.10 vs \$(0.04) Est.

Financial news for ALKS dated on 2017-10-26: Alkermes Reports Q3 Adj. EPS \$0.03 vs \$(0.01) Est., Sales \$217.4M vs \$231M Est.

Financial news for ALKS dated on 2017-10-18: Alkermes Publishes PR Titled New Study Comparing Effectiveness of Extended-Release Naltrexone to Buprenorphine-Naloxone for Opioid Dependence Published in JAMA Psychiatry

Financial news for ALKS dated on 2017-10-18: Stat News Reporter Rebecca Robbins Tweets: Big study news: Compared head to head, Vivitrol works as well as Suboxone for short-term abstinence from heroin.

Financial news for ALKS dated on 2017-10-16: Barclays Downgrades Alkermes plc - Ordinary Shares to Equal-Weight

Financial news for ALKS dated on 2017-09-18: Alkermes Gives Update on ARISTADA

Financial news for ALKS dated on 2017-09-08: Watch These 8 Huge Call Purchases In Friday Trade

Financial news for ALKS dated on 2017-09-07: Benzinga's Option Alert Recap From September 7

Financial news for ALKS dated on 2017-09-07: Alkermes Option Alert: Sep 15 \$50 Calls Sweep (2) at the Bid: 4551 @ \$0.61 vs 188 OI; Ref=\$49.49

Financial news for ALKS dated on 2017-08-24: Playing The US Pharma Space: Buy Portola, Hold Corvus, Sell Teva

Financial news for ALKS dated on 2017-08-21: Alkermes Initiates Rolling Submission of ALKS 5461 NDA for Major Depressive Disorder

Financial news for ALKS dated on 2017-08-21: Watch These 5 Huge Put Purchases In Monday Trade

Financial news for ALKS dated on 2017-08-18: Alkermes Option Alert: Nov 17 \$45 Puts Sweep (29) at the Bid: 740 @ \$1.082 vs 39 OI; Ref=\$50.68

Financial news for ALKS dated on 2017-08-07: Every Generation Has Its Drug: How People Are Dealing With Opioids, The New (Old) Thing

Financial news for ALKS dated on 2017-07-27: Alkermes 10-Q Shows Co. Received Subpoena From Office Of US Attorney For Docs Related To VIVITROL On Jun. 22, 2017

Financial news for ALKS dated on 2017-07-27: Alkermes 10-Q Filing Just Out

Financial news for ALKS dated on 2017-07-27: Alkermes plc Reports Q2 Adj. EPS \$0.01 vs \$(0.01) Est., Sales \$218.8M vs \$216.9M Est.

Financial news for ALKS dated on 2017-07-05: Attention Biotech Investors: Keep Your Date With July PDUFA Action-Days

Financial news for ALKS dated on 2017-06-29: UPDATE: Alkermes Says 91% Of Patients Who Received ALKS 3831 Completed Study vs 89% Who Received Olanzapine, 83% Who Received Placebo

Financial news for ALKS dated on 2017-06-29: Alkermes Reports Prelim. Results From Phase 3 Antipsychotic Efficacy Study Of ALKS 3831 For Treatment Of Schizophrenia: Showed Efficacy Statistically Superior To Placebo, Similar To Olanzapine In ENLIGHTEN-1 Study

Financial news for ALKS dated on 2017-06-15: Goldman Sachs Global Healthcare Conference Concludes Today, Presenters Include: Gilead, Tesaro, Ironwood Pharmaceuticals and Alkermes

Financial news for ALKS dated on 2017-06-13: Leerink Swann Downgrades Alkermes plc - Ordinary Shares to Market Perform

Financial news for ALKS dated on 2017-06-12: Alkermes Looks To Capitalize On Opioid Epidemic Through Aggressive Lobbying

Financial news for ALKS dated on 2017-06-06: Jefferies Health Care Conference Begins Today, Presenters Include: Agilent Technologies, Civitas Solutions, Aeri Pharmaceuticals, Alkermes, Alnylam Pharmaceuticals, Heron Therapeutics

Financial news for ALKS dated on 2017-06-06: Alkermes Reports FDA Approved 2-Month ARISTADA for Treatment of Schizophrenia

Financial news for ALKS dated on 2017-06-05: Remider: Alkermes Has ARISTADA PDUFA Date Today

Financial news for ALKS dated on 2017-05-30: Tracking The Busy June PDUFA Calendar

Financial news for ALKS dated on 2017-05-24: Companies Holding Shareholder Meetings Today Include: Paypal, Towne Bank, Alkermes, Arbutus Biopharma, Aerohive, Ionis, HSN, Hilton, Ocwen Financial, McDonald's, Lumber Liquidators, Shutterfly, & E.L.F. Beauty

Financial news for ALKS dated on 2017-04-27: Alkermes Reports Q1 Adj. EPS \$(0.18) vs \$(0.08) Est., Sales \$191.8M vs \$197.3M Est.

Financial news for ALKS dated on 2017-04-06: Your Cheat Sheet For Q1 Biotech Earnings

Financial news for ALKS dated on 2017-03-31: Forward Pharma Falls On Biogen Patent Victory Over MS Drug Ingredient

Financial news for ALKS dated on 2017-03-31: Alkermes Shares Turn Negative Over Last Few Mins, Now Down ~0.1% Following Breaking News in MS Space

Financial news for ALKS dated on 2017-03-16: Alkermes Reports Initiation of Phase 3 Gastrointestinal Tolerability Study of ALKS 870 for Treatment of MS

Financial news for ALKS dated on 2017-02-15: Q4 2016 Real-Time Call Brief

Financial news for ALKS dated on 2017-02-15: Alkermes Q4 EPS \$0.15 vs \$0.04 Est, Revenue \$213.5M vs \$206.4M Est

Financial news for ALKS dated on 2017-01-20: Wall Street's M&A Chatter From January 19

Financial news for ALKS dated on 2016-12-16: Cantor Fitzgerald Initiates Coverage On Alkermes at Neutral, Announces \$52.00 Target

Financial news for ALKS dated on 2016-11-30: Alkermes Prevails In Luya Pharma IPR Challenge Against '061 Various Drug Patent

Financial news for ALKS dated on 2016-11-28: Recro's Late-Stage IV Meloxicam Trial Results Rocket Stock Skyward

Financial news for ALKS dated on 2016-11-23: Eli Lilly's Solanezumab Failure: Alzheimer's Treatment Space Feels Aftershock

Financial news for ALKS dated on 2016-11-16: Jefferies London Healthcare Conference Taking Place Today

Financial news for ALKS dated on 2016-11-02: Alkermes Reports Q3 EPS \$(0.09) vs. Est. \$(0.06), Rev. \$180.2M vs. Est. \$186M

Financial news for ALKS dated on 2016-10-26: Alkermes Popping On Volume, Hearing Company To Appear On Cramer's Mad Money

Financial news for ALKS dated on 2016-10-21: JPMorgan Upgrades Alkermes As The Company Adds To Its Already Valuable Portfolio

Financial news for ALKS dated on 2016-10-21: Mid-Afternoon Market Update: Skechers Falls On Earnings Miss; Reynolds American Shares Spike Higher

Financial news for ALKS dated on 2016-10-21: Cerecor Shares Moving In Sympathy To Positive Alkermes' Trial News

Financial news for ALKS dated on 2016-10-21: 15 Biggest Mid-Day Gainers For Friday

Financial news for ALKS dated on 2016-10-21: Mid-Day Market Update: Alkermes Surges Following Positive Data For Depression Drug Trial; Stone Energy Shares Slide

Financial news for ALKS dated on 2016-10-21: Alkermes Rallies Off Positive Data For Depression Drug Trial

Financial news for ALKS dated on 2016-10-21: Benzinga's Volume Movers

Financial news for ALKS dated on 2016-10-21: Benzinga's Volume Movers

Financial news for ALKS dated on 2016-10-21: Benzinga's Volume Movers

Financial news for ALKS dated on 2016-10-21: Mid-Morning Market Update: Markets Open Lower; McDonald's Beats Q3 Estimates

Financial news for ALKS dated on 2016-10-21: Alkermes Shares Move Higher on Positive Jim Cramer Comments

Financial news for ALKS dated on 2016-10-21: The Market In 5 Minutes: Big Earnings In Focus And A Tobacco Giant In The Making

Financial news for ALKS dated on 2016-10-21: Benzinga's Top Upgrades

Financial news for ALKS dated on 2016-10-21: 16 Stocks Moving In Friday's Pre-Market Session

Financial news for ALKS dated on 2016-10-21: JP Morgan Upgrades Alkermes plc - Ordinary Shares to Overweight

Financial news for ALKS dated on 2016-10-20: Alkermes Spikes 40% After Positive Data From Depression Treatment Trial

Financial news for ALKS dated on 2016-10-20: Alkermes Meets Primary Endpoint In FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder

Financial news for ALKS dated on 2016-10-04: Leerink Swann Assumes Alkermes at Outperform, Announces \$57.00 PT

Financial news for ALKS dated on 2016-10-03: Recro Pharma Offers A Non-Opioid Alternative For Pain Management; Brean Assumes With Buy Rating

Financial news for ALKS dated on 2016-10-03: Alkermes Initiates Clinical Study of ALKS 3831

Financial news for ALKS dated on 2016-09-16: Alkermes Shares Up ~\$0.45 Over Last Few Mins as Traders Passing Around Positive Mention from Motley Fool

Financial news for ALKS dated on 2016-09-09: 15 Stocks Which Rallied Four Days, Then Sold Off Yesterday

Financial news for ALKS dated on 2016-08-18: 11 Biopharma CEOs To Follow On Twitter

Financial news for ALKS dated on 2016-08-08: Alkermes Reports FDA Submission of sNDA for Two-Month Dosing Option of ARISTADA for Schizophrenia

Financial news for ALKS dated on 2016-07-29: 8-K from Alkermes Shows District Court Issued Unambiguous Opinion In Favor of Co., FDA, Affirming All Respect's FDA's Decision to Approve ARISTADA for Treatment of Schizophrenia

Financial news for ALKS dated on 2016-07-28: Alkermes Raises, Narrows FY16 Adj. EPS Outlook from \$(0.36)-\$(0.16) to \$(0.23)-\$(0.03) vs \$(0.26) Est.

Financial news for ALKS dated on 2016-07-28: Alkermes Reports Q2 Adj. EPS \$(0.01) vs \$(0.10) Est., Sales \$195.2M vs \$174.3M Est.

Financial news for ALKS dated on 2016-07-26: Cowen & Company Upgrades Alkermes to Market Perform

Financial news for ALKS dated on 2016-07-12: Barclays Adjusts Price Targets On AK Steel, CONSOL Energy And Others

Financial news for ALKS dated on 2016-07-12: Barclays Sees 32% Upside In Alkermes Shares, Says 2016 Vivitrol Sales 'Could Easily Top Guidance'

Financial news for ALKS dated on 2016-05-27: Option Alert: ALKS Jun16 46.0 Calls: 500 @ ASK \$2.30: 517 traded vs 75 OI: \$45.71 Ref

Financial news for ALKS dated on 2016-05-26: Benzinga's Top Initiations

Financial news for ALKS dated on 2016-05-26: Evercore ISI Group Initiates Coverage on Alkermes at Buy

Financial news for ALKS dated on 2016-05-25: Alkermes Initiates Phase 1 Clinical Trial Of Immuno-Oncology Drug Candidate ALKS 4230

Financial news for ALKS dated on 2016-05-25: Alkermes Reports Initiation of Phase 1 Study of ALKS 4230

Financial news for ALKS dated on 2016-05-20: 10 Biggest Mid-Day Gainers For Friday

Financial news for ALKS dated on 2016-05-20: Alkermes Shares Spiking, Traders Passing Around SPeculation Of Possible Sale Around \$60/Shr

Financial news for ALKS dated on 2016-05-05: Cowen & Company Assumes Alkermes at Market Perform

Financial news for ALKS dated on 2016-05-03: Shares of Alkermes Sell Off then Rebound Following FDA Safety Alert on Aripiprazole

Financial news for ALKS dated on 2016-05-03: Alkermes Sells Off to Low of \$37.89 on Vol

Financial news for ALKS dated on 2016-04-28: Alkermes Reports Q1 Adj. EPS \$(0.16) vs \$(0.21) Est., Sales \$157M vs \$153.4M Est.

Financial news for ALKS dated on 2016-04-28: Alkermes to Initiate Second Trial of ALKS 7119

Financial news for ALKS dated on 2016-03-31: Alkermes Reports Study on ER Naltrexone in Opioid-Dependent Patients Involved in Criminal Justice System Publied in NEJoM

Financial news for ALKS dated on 2016-02-25: Alkermes Reports Q4 EPS \$(0.15) vs. Est. \$(0.18), Rev. \$163.1M vs. Est. \$162.6M

Financial news for ALKS dated on 2016-02-10: Alkermes Reports Initiation of Second Phase 3 Study of ALKS 3831 for Schizophrenia

Financial news for ALKS dated on 2016-01-28: 7 Biotech Traders Pick Their Favorite Stocks For 2016

Financial news for ALKS dated on 2016-01-25: Alkermes Says Expecting Results of Phase 1 Study in 2H 2016

Financial news for ALKS dated on 2016-01-21: Mid-Afternoon Market Update: Crude Oil Surges Over 4%; Alkermes Shares Slide Following Announcement of Failed Depression Drug Trial

Financial news for ALKS dated on 2016-01-21: Mid-Day Market Update: US Stocks Turn Higher; Plexus Shares Gain On Strong Results

Financial news for ALKS dated on 2016-01-21: Stocks Hitting 52-Week Lows

Financial news for ALKS dated on 2016-01-21: Mid-Morning Market Update: Markets Drop; Verizon Profit Tops Estimates

Financial news for ALKS dated on 2016-01-21: UPDATE: Cowen & Company Lowers Alkermes PT to \$50.00

Financial news for ALKS dated on 2016-01-21: Cowen & Company Downgrades Alkermes to Market Perform

Financial news for ALKS dated on 2016-01-21: 10 Stocks Moving In Thursday's Pre-Market Session

Financial news for ALKS dated on 2016-01-21: Alkermes -30% Premarket @\$42.33 Following Announcement of Failed Depression Drug Trial

Financial news for ALKS dated on 2016-01-21: Alkermes Announces Neither Study in FORWARD-3, FORWARD-4 for ALKS 5461 in Major Depressive Disorder Met Primary Endpoint

Financial news for ALKS dated on 2016-01-20: Option Alert: ALKS Feb16 70.0 Calls Sweep: 550 @ ASK \$1.32: 556 traded vs 750 OI: Earnings 2/23 \$57.50 Ref

Financial news for ALKS dated on 2015-12-28: Option Alert: ALKS Feb16 70.0 Puts: 500 @ ASK \$2.50: 500 traded vs 1148 OI: \$80.31 Ref

Financial news for ALKS dated on 2015-12-16: UPDATE: Alkermes Highlights Data Announced from Supportive Study in FORWARD Pivotal Program for ALKS 5461 in Major Depressive Disorder

Financial news for ALKS dated on 2015-12-16: UPDATE: Alkermes Says Pivotal Programs for ALKS 3831 for Schizophrenia, ALKS 8700 for MS Initiated

Financial news for ALKS dated on 2015-12-16: Alkermes Reports Achievement of Milestones for CNS Medicines in Proprietary Product, Pipeline Portfolio

Financial news for ALKS dated on 2015-10-29: Alkermes Reports Q3 Adj. Loss of \$0.18/Share vs Loss of \$0.21/Share Est., Sales \$152.7M vs \$151.8M Est.

Financial news for ALKS dated on 2015-09-30: Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Years

Financial news for ALKS dated on 2015-09-02: Non-Opioid Therapeutics And Significant Pain Treatments Make For A Buy Rating

Financial news for ALKS dated on 2015-09-01: Benzinga's Volume Movers

Financial news for ALKS dated on 2015-09-01: Morning Market Gainers

Financial news for ALKS dated on 2015-09-01: Underappreciated Leader Skips Over Equal-Weight In Double Upgrade

Financial news for ALKS dated on 2015-09-01: Benzinga's Top Upgrades

Financial news for ALKS dated on 2015-09-01: Benzinga's Top #PreMarket Gainers

Financial news for ALKS dated on 2015-09-01: Morgan Stanley Upgrades Alkermes to Overweight, Raises PT to \$85.00

Financial news for ALKS dated on 2015-08-21: Alkermes Offers Update on FDA Review of

Aristada for Treatment of Schizophrenia: FDA Advised Co. Will Not Be Able to Close Review of NDA

Financial news for ALKS dated on 2015-07-30: Alkermes Reports Q2 Adj. Loss of \$0.09/Share vs Loss of \$0.10/Share Est., Sales \$151.4M vs \$142.8M Est.

Financial news for ALKS dated on 2015-06-17: Alkermes CEO Says Co Not For Sale -Wall Street Journal

Financial news for ALKS dated on 2015-06-16: Benzinga's M&A Chatter for Tuesday June 16, 2015

Financial news for ALKS dated on 2015-06-16: Alkermes Declines Comment on Rumored Potential Bid from Merck

Financial news for ALKS dated on 2015-06-16: Alkermes Shares Off the Highs; Shares Moving Higher on Takeover Chatter, Upcoming Presentation of Data from Late-Stage CNS Portfolio

Financial news for ALKS dated on 2015-06-16: Hearing Unconfirmed Market Chatter of Potential Merck Bid for Alkermes

Financial news for ALKS dated on 2015-06-16: US Stock Futures Decline Ahead Of Housing Starts Report

Financial news for ALKS dated on 2015-06-16: Alkermes to Present Data From Late-Stage CNS Portfolio at Upcoming American Society of Clinical Psychopharmacology Annual Meeting

Financial news for ALKS dated on 2015-06-09: Alkermes Reports Phase 3 Study Results for Aripiprazole Lauroxil Published in JCP

Financial news for ALKS dated on 2015-06-09: Aripiprazole Lauroxil Phase 3 Schizophrenia Study Results Are Published in Journal of Clinical Psychiatry

Financial news for ALKS dated on 2015-05-29: US Stock Futures Edge Lower; GDP Report In Focus

Financial news for ALKS dated on 2015-05-29: Alkermes to Present Clinical Data on ALKS 8700 at Annual Meeting of the Consortium of Multiple Sclerosis Centers

Financial news for ALKS dated on 2015-05-26: Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest EPS Growth Forecast For Next 5 Years

Financial news for ALKS dated on 2015-05-21: Benzinga's Top Initiations

Financial news for ALKS dated on 2015-05-21: 4 SMID-Cap Biotechs Barclays Just Confessed It Loves

Financial news for ALKS dated on 2015-05-21: Barclays Initiates Alkermes With Overweight

Financial news for ALKS dated on 2015-05-21: Barclays Initiates Coverage on Alkermes at Overweight, Announces \$74.00 PT

Financial news for ALKS dated on 2015-04-30: Alkermes Reports Q1 Adj EPS \$0.06 Vs Est -\$0.03, Sales \$161.2M Vs Est \$146.6M

Financial news for ALKS dated on 2015-04-13: Alkermes Will Start RDB 1450 Phase One Study in Q3

Financial news for ALKS dated on 2015-04-06: Alkermes Reports Positive Topline Results from Full Six-Month Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia

Financial news for ALKS dated on 2015-03-27: Alkermes 'Taking A Pause,' Citi Says

Financial news for ALKS dated on 2015-03-27: Citigroup Downgrades Alkermes to Neutral, Lowers PT to \$71.00

Financial news for ALKS dated on 2015-03-12: UPDATE: Morgan Stanley Downgrades Alkermes As Good News Is Appreciated

Financial news for ALKS dated on 2015-03-12: Morgan Stanley Downgrades Alkermes to Underweight, Announces \$61.00 PT

Financial news for ALKS dated on 2015-03-09: Recro Pharma to Acquire IV/IM Meloxicam, Gainesville, GA GMP Manufacturing Facility, Business Unit from Alkermes for \$50M

Financial news for ALKS dated on 2015-03-02: US Stock Futures Edge Higher Ahead Of

Economic Data

Financial news for ALKS dated on 2015-03-02: Alkermes Announces New Drug Candidate, ALKS 7119, for Treatment of Alzheimer's Agitation, MDD, Other CNS Diseases

Financial news for ALKS dated on 2015-02-24: Alkermes Announces Results From Phase 1 Study of ALKS 7106

Financial news for ALKS dated on 2015-02-24: Alkermes Reports Q4 Adj. EPS \$0.11 vs \$0.04 Est., Sales \$175.2M vs \$161.7M Est.; Sees FY15 Sales \$640M-\$670M vs \$674.32M Est.

Financial news for ALKS dated on 2015-02-11: Alkermes Shares Near High; Co Presenting at Leerink Conference

Financial news for ALKS dated on 2015-02-09: Alkermes Reports Positive Topline Results from Phase 1 Study of ALKS 8700 for Treatment of MS

Financial news for ALKS dated on 2015-01-14: Why Citigroup Placed An \$85 Price Target On Shares Of Alkermes

Financial news for ALKS dated on 2015-01-12: Biotechs Presenting At The J.P. Morgan Healthcare Conference: Day 2

Financial news for ALKS dated on 2015-01-07: Morning Market Gainers

Financial news for ALKS dated on 2015-01-07: Benzinga's Top #PreMarket Gainers

Financial news for ALKS dated on 2015-01-07: Alkermes Announces Positive Topline Results From Phase 2 Study, Primary Endpoint Met

Financial news for ALKS dated on 2015-01-06: Benzinga's Volume Movers

Financial news for ALKS dated on 2014-12-15: Alkermes Initiates Clinical Study of Extended Durations of Aripiprazole Lauroxil for Treatment of Schizophrenia

Financial news for ALKS dated on 2014-12-08: 3 Biotech ETFs Rally On Merger News

Financial news for ALKS dated on 2014-11-11: Top 4 Stocks In The Drug Delivery Industry With The Highest Revenue

Financial news for ALKS dated on 2014-10-29: Alkermes plc Reports Q3 EPS of \$0.03 vs \$0.02 Est; Revenue of \$160.0M vs \$155.53M Est

Financial news for ALKS dated on 2014-10-22: Alkermes' NDA for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by FDA

Financial news for ALKS dated on 2014-10-20: Bank Of America Q3 Small & Mid-Cap Biotech Preview

Financial news for ALKS dated on 2014-09-03: Alkermes PLC Announces Completion Of Patient Enrollment In Phase 2 Study Of ALKS 3831, A Novel, Broad-Spectrum Oral Antipsychotic

Financial news for ALKS dated on 2014-08-26: Alkermes Initiates Phase 1 Clinical Study of ALKS 7106 for Treatment of Pain

Financial news for ALKS dated on 2014-08-25: US Stock Futures Rise Ahead Of Economic Data

Financial news for ALKS dated on 2014-08-25: Alkermes Submits NDA to FDA for Aripiprazole Lauroxil for Treatment of Schizophrenia

Financial news for ALKS dated on 2014-08-14: Morgan Stanley Sees EPS Below Consensus, Robust Pipeline For Alkermes plc

Financial news for ALKS dated on 2014-07-31: Alkermes plc Lowers FY2014 EPS Guidance from \$0.41-0.54 to \$0.19-0.32 vs \$0.51 Est

Financial news for ALKS dated on 2014-07-31: Alkermes plc Reports Q2 EPS of \$0.11 vs \$0.14 Est; Revenue of \$153.40M vs \$147.51M Est

Financial news for ALKS dated on 2014-07-31: Alkermes Says on Track for Aripiprazole Lauroxil NDA Submission in Q3 2014

Financial news for ALKS dated on 2014-07-30: Alkermes Announces Initiation of Clinical Study For ALKS 5461

Financial news for ALKS dated on 2014-07-17: Alkermes Announces Initiation of Phase 1

Study of ALKS 8700

Financial news for ALKS dated on 2014-07-09: Alkermes Reports Notices of Allowance for US Patents for Four CNS Pipeline Candidates

Financial news for ALKS dated on 2014-06-18: Alkermes Announces Aripiprazole Met Endpoint

Financial news for ALKS dated on 2014-06-16: Cramer Says Eaton, TE Connectivity, Pentair, Tyco, Alkermes, Jazz Pharma, Weatherford May be Takeover Targets, Similar Situations to Covidien Regarding Tax Benefit

Financial news for ALKS dated on 2014-06-10: Alkermes Reports Commencement of FORWARD-3, FORWARD-4 Efficacy Studies in Pivotal Program for ALKS 5461

Financial news for ALKS dated on 2014-04-30: Top 4 NASDAQ Stocks In The Drug Delivery Industry With The Highest Revenue

Financial news for ALKS dated on 2014-04-10: Mizuho Securities Upgrades Alkermes plc to Buy, Raises PT to \$61.00

Financial news for ALKS dated on 2014-04-08: Market Wrap For April 8: Markets Bounce Higher As Earnings Season Begins

Financial news for ALKS dated on 2014-04-08: Mid-Afternoon Market Update: Markets Recover Slightly as Coal Shows Strength

Financial news for ALKS dated on 2014-04-08: Mid-Day Market Update: US Stocks Gain; Gigamon Shares Dip On Lower Forecast

Financial news for ALKS dated on 2014-04-08: Benzinga's Volume Movers

Financial news for ALKS dated on 2014-04-08: Mid-Morning Market Update: Markets Mixed; A. Schulman Lifts Profit Outlook

Financial news for ALKS dated on 2014-04-08: Morning Market Movers

Financial news for ALKS dated on 2014-04-08: UPDATE: Alkermes Shares Rise 7% Premarket on Release of Positive Topline Results From Pivotal Phase 3 Study of Aripiprazole Lauroxil

Financial news for ALKS dated on 2014-04-08: Alkermes Announces Positive Topline Results From Pivotal Phase 3 Study of Aripiprazole Lauroxil

Financial news for ALKS dated on 2014-04-02: Benzinga's Top Initiations

Financial news for ALKS dated on 2014-04-02: Credit Suisse Initiates Coverage on Alkermes plc at Outperform, Announces \$57.00 PT

Financial news for ALKS dated on 2014-03-06: Alkermes Announces Initiation of ALKS-5461 PIVOTAL Clinical Trial

Financial news for ALKS dated on 2014-02-27: Alkermes plc Sees FY2014 EPS \$0.41-0.54; Sees Sales \$580.0M-610.0M

Financial news for ALKS dated on 2014-02-27: Alkermes plc Reports Q4 EPS of \$0.27 vs \$0.20 Est; Revenue of \$154.50M vs \$142.93M Est

Financial news for ALKS dated on 2014-01-13: Alkermes Files Prospectus for 5.9M Shares

Financial news for ALKS dated on 2014-01-08: Alkermes Announces Advances in Late-Stage CNS Pipeline

Financial news for ALKS dated on 2014-01-06: Alkermes Receives Notice of Allowance of US Patent for Novel Fumarate Prodrug for MS

Financial news for ALKS dated on 2013-12-09: Alkermes Presents Data on Aripiprazole Lauroxil and ALKS 5461 at 52nd Annual ACNP Meeting

Financial news for ALKS dated on 2013-12-05: UBS Downgrades Alkermes plc to Neutral

Financial news for ALKS dated on 2013-10-31: CORRECTION: Alkermes plc Reports Q2 EPS of \$0.22 vs \$0.23 Est; Revenue of \$139.80M vs \$137.48M Est

Financial news for ALKS dated on 2013-10-31: Alkermes plc Reports Q3 EPS of \$0.22 vs \$0.23 Est; Revenue of \$139.80M vs \$137.48M Est

Financial news for ALKS dated on 2013-10-17: UPDATE: Citigroup Raises PT on Alkermes

on Multiple Value Opportunities

Financial news for ALKS dated on 2013-10-09: Alkermes, FDA Agree on Deal for Elements of ALKS 5461 Development Program

Financial news for ALKS dated on 2013-10-01: Morgan Stanley Downgrades Alkermes plc to Equalweight

Financial news for ALKS dated on 2013-09-20: Top 4 Stocks In The Drug Delivery Industry With The Highest Cash

Financial news for ALKS dated on 2013-08-01: Moody's Upgrades Alkermes to Ba3; Outlook Positive

Financial news for ALKS dated on 2013-06-19: UPDATE: Bank of America Lowers PO on Alkermes on Reduced Bydureon Forecast

Financial news for ALKS dated on 2013-05-31: Alkermes Issues Positive Results from Phase 2 Study of ALKS 5461

Financial news for ALKS dated on 2013-05-31: Alkermes Phase 2 Clinical Study of ALKS 5461 in Major Depressive Disorder Met Primary Endpoint

Financial news for ALKS dated on 2013-05-29: Leerink Swann Initiates Coverage on Alkermes plc at Outperform

Financial news for ALKS dated on 2013-05-28: A Peek Into The Market Before The Trading Starts

Financial news for ALKS dated on 2013-05-28: Alkermes Announces Positive Results from Phase 1 Study of ALKS 3831 Treatment for Schizophrenia

Financial news for ALKS dated on 2013-05-24: MKM Partners Downgrades Alkermes plc to Sell

Financial news for ALKS dated on 2013-05-24: Argus Research Downgrades Alkermes plc to Sell

Financial news for ALKS dated on 2013-05-23: Alkermes plc Reports Q4 EPS of \$0.40 Which May Not Compare \$0.17 Est

Financial news for ALKS dated on 2013-05-22: Top 4 Stocks In The Drug Delivery Industry With The Lowest PEG Ratio

Financial news for ALKS dated on 2013-05-10: The Week Ahead: Full Slate of Economic Data; Earnings From Cisco, Wal-Mart and Deere

Financial news for ALKS dated on 2013-04-26: UPDATE: Bank of America Downgrades Alkermes to Underperform on ALKS-5461 Market Opportunity

Financial news for ALKS dated on 2013-04-26: Bank of America Downgrades Alkermes plc to Underperform, Raises PO to \$29.00

Financial news for ALKS dated on 2013-04-22: Lazard Capital Markets Downgrades Alkermes plc to Neutral

Financial news for ALKS dated on 2013-04-18: Mizuho Downgraded Alkermes Following 16% Surge on Wednesday

Financial news for ALKS dated on 2013-04-17: Market Wrap for Wednesday, April 17: Stocks Plunge Again Along With Euro

Financial news for ALKS dated on 2013-04-17: Mid-Afternoon Market Update: Markets Remain Down, ABIOMED Rises

Financial news for ALKS dated on 2013-04-17: Mid-Day Market Update: Cirrus Logic Plunges On Weak Forecast, Atlas Energy Rises

Financial news for ALKS dated on 2013-04-17: Stocks Hitting 52-Week Highs

Financial news for ALKS dated on 2013-04-17: Mid-Morning Market Update: Markets Move Lower, Bank of America Posts Downbeat Q1 Profit

Financial news for ALKS dated on 2013-04-17: Alkermes Announces Positive Phase 2 Results from Clinical Study of ALKS 5461 for Major Depressive Disorder

Financial news for ALKS dated on 2013-04-09: Alkermes Reducing Headcount by 130 Jobs, Sees Restructuring Charge \$12.5M

Financial news for ALKS dated on 2013-02-19: Alkermes Maintains FY13 Adj. Net Income Guidance of \$135-155M

Financial news for ALKS dated on 2013-02-01: Bank of America Downgrades Alkermes plc to Neutral, Raises PO to \$24.00

Financial news for ALKS dated on 2013-02-01: Bank of America Downgrades Alkermes plc to undefined, Raises PO to \$24.00

Financial news for ALKS dated on 2013-01-31: Elan Selling Remaining Stake in Alkermes, 7.75M Shares

Financial news for ALKS dated on 2013-01-31: Alkermes plc Raises FY2013 EPS Guidance from \$0.88-1.02 to \$0.99-1.13 vs \$0.95 Est

Financial news for ALKS dated on 2013-01-31: Alkermes plc Reports Q3 EPS of \$0.34 vs \$0.23 Est

Financial news for ALKS dated on 2013-01-23: MKM Partners Downgrades Alkermes plc to Neutral, Maintains \$23.00 PT

Financial news for ALKS dated on 2013-01-17: UPDATE: Credit Suisse Initiates Alkermes at Neutral; Looking For Better Entry

Financial news for ALKS dated on 2013-01-17: Credit Suisse Initiates Coverage on Alkermes plc at Neutral, Announces \$24.00 PT

Financial news for ALKS dated on 2013-01-15: Citigroup Maintains Buy on Alkermes plc, Raises PT to \$30.00

Financial news for ALKS dated on 2013-01-14: Top 4 Stocks In The Drug Delivery Industry With The Highest EPS Estimates For The Next Quarter

Financial news for ALKS dated on 2013-01-10: Editor of Little Bear Blog is Adding to Alkermes Long Position

Financial news for ALKS dated on 2013-01-10: UPDATE: Morgan Stanley Upgrades Alkermes plc to Overweight on New Pipeline Opportunities

Financial news for ALKS dated on 2013-01-10: Morgan Stanley Upgrades Alkermes plc to Overweight, Raises PT to \$26.00

Financial news for ALKS dated on 2013-01-07: Alkermes Shares Spiking Above 20-Day SMA, \$21 Level Following CEO Appearance on CNBC, Said Optimistic for Raise in Vivitrol Use by Prisoners

Financial news for ALKS dated on 2013-01-03: Alkermes Announces Notice of Allowance of USPTO Application for Aripiprazole Lauroxil

Financial news for ALKS dated on 2013-01-03: Alkermes Announces Positive Results from Phase 1 Study of ALKS 3831

Financial news for ALKS dated on 2012-11-27: UPDATE: Morgan Stanley Initiates Alkermes at Equal-Weight on Commercialization Visibility

Financial news for ALKS dated on 2012-11-27: Morgan Stanley Initiates Coverage Alkermes at Equalweight, Announces PT of \$21

Financial news for ALKS dated on 2012-11-27: Morgan Stanley Initiates Coverage Alkermes at Equalweight, Announces PT of \$21

Financial news for ALKS dated on 2012-11-16: Mizuho Initiated Coverage on Alkermes at Buy, Announces PT of \$27

Financial news for ALKS dated on 2012-11-07: Alkermes' Corporate Presentation to be Webcast at Two Upcoming Conferences

Financial news for ALKS dated on 2012-11-01: JP Morgan Maintains Alkermes at Overweight, Raises PT from \$25 to \$26

Financial news for ALKS dated on 2012-11-01: Alkermes Boosts FY Sales Outlook from \$490-530M to \$510-540M vs \$516.3M Est, EPS from \$(0.15)-(0.30) to \$0.00-(0.11) vs \$(0.14) Est

Financial news for ALKS dated on 2012-11-01: Alkermes Reports Q2 EPS \$0.17 vs \$0.11 Est; Revenues \$124M vs \$121.62M Est

Financial news for ALKS dated on 2012-09-25: UPDATE: Alkermes Guides FY EPS \$0.69-0.84, Had Seen \$0.62-0.77

Financial news for ALKS dated on 2012-09-25: Alkermes Closes Debt Refinancing

Financial news for ALKS dated on 2012-09-14: Alkermes Said to be Adding \$75M Term Loan Due 2016; 7 Year Term Loan Reduced to \$300M From \$375M -Bloomberg

Financial news for ALKS dated on 2012-07-18: Jefferies Reiterates Buy Rating, \$24 PT on Alkermes

Financial news for ALKS dated on 2012-07-17: Alkermes Receives Positive Mad Money/Jim Cramer Mention -CNBC

Financial news for ALKS dated on 2012-05-31: UPDATE: J.P. Morgan Lowers Alkermes' PT

Financial news for ALKS dated on 2012-05-30: UPDATE: Alkermes Says Alkermes Phase 2 Study of ALKS 37 Did Not Satisfy Pre-Specified Criteria; Will Not Advance to Phase 3

Financial news for ALKS dated on 2012-05-30: Alkermes Announces Results from Phase 2 Study of ALKS 37 for Treatment of Opioid-Induced Constipation

Financial news for ALKS dated on 2012-05-29: Alkermes Presents Positive Clinical Data of ALKS 5461 at 52nd Annual New Clinical Drug Evaluation Unit Meeting

Financial news for ALKS dated on 2012-05-18: UPDATE: Goldman Sachs Reiterates Neutral Rating, Lowers PT for Alkermes

Financial news for ALKS dated on 2012-05-17: Alkermes Reports Q4 EPS \$0.12 vs \$-0.16 Est; Revenues \$130.5M vs \$125.88M Est

Financial news for ALKS dated on 2012-05-10: Alkermes CEO Pops: 'The Difficult Part of Being a Pioneer is You Need to Blaze Your Own Trail'

Financial news for ALKS dated on 2012-05-10: Alkermes CEO Pops: 'Biotech is a Good Place for Large Companies to Hunt Because They Need New Drugs'

Financial news for ALKS dated on 2012-05-10: Alkermes CEO Pops: 'We are Inventing New Drugs That Will Add Value Like Lipitor Has Done for Years'

Financial news for ALKS dated on 2012-05-10: Jim Cramer Interviews CEO Richard F. Pops of Alkermes on Mad Money

Financial news for ALKS dated on 2012-05-10: PREVIEW: Jim Cramer to Interview CEO of Alkermes on Mad Money

Financial news for ALKS dated on 2012-03-08: Alkermes plc Prices Secondary Offering of 21,000,000 Ordinary Shares Held by Elan

Financial news for ALKS dated on 2012-03-07: Alkermes Reports Secondary Offering of 13.9M Shares Held by Elan

Financial news for ALKS dated on 2012-03-07: Alkermes Announces a Secondary Offering of 13,900,000 Ordinary Shares Held by Elan

Financial news for ALKS dated on 2012-03-05: Market Roundup

Financial news for ALKS dated on 2012-03-05: Alkermes Appoints Mark Stejbach as Chief Commercial Officer

Financial news for ALKS dated on 2012-02-16: Alkermes Files Resale Shelf Registration in Connection with Elan Shareholder Agreement

Financial news for ALKS dated on 2012-02-13: BYDUREON(tm), First and Only Once-Weekly Type 2 Diabetes Treatment, Now Available in U.S. Pharmacies

Financial news for ALKS dated on 2012-02-02: Amylin Pharmaceuticals Continues to Soar in Wake of Bydureon Approval

Financial news for ALKS dated on 2012-01-31: Alkermes Initiates Open-Label Pilot Study of VIVITROL to Evaluate Impact on Re-Arrest and Re-Incarceration in Offenders with History of Opioid Dependence

Financial news for ALKS dated on 2012-01-30: Benzinga's M&A Chatter for Monday January 30, 2012

Financial news for ALKS dated on 2012-01-30: Benzinga's Top Pre-Market Gainers

Financial news for ALKS dated on 2012-01-27: Trading Resumed in Alkermes

Financial news for ALKS dated on 2012-01-27: Amylin Pharmaceuticals, Alkermes Resume

Trading

Financial news for ALKS dated on 2012-01-27: PREVIEW: Amylin Pharmaceuticals, Alkermes to Resume Trading at 4:15pm

Financial news for ALKS dated on 2012-01-27: UPDATE: FDA Approves BYDUREON, for Type 2 Diabetes

Financial news for ALKS dated on 2012-01-27: UPDATE: Amylin, Alkermes Drug Approved by FDA

Financial news for ALKS dated on 2012-01-27: UPDATE: No Decision Made by FDA on Amylin, Alkermes -Bloomberg

Financial news for ALKS dated on 2012-01-27: Amylin, Alkermes Win US Clearance for Weekly Diabetes Shot

Financial news for ALKS dated on 2012-01-27: Alkermes Halted, News Pending

Financial news for ALKS dated on 2012-01-25: Benzinga's Volume Gainers

Financial news for ALKS dated on 2012-01-20: Best Specialty Pharma Stocks Picked by UBS

Financial news for ALKS dated on 2012-01-11: CORRECTION: Bydureon Drug Approval Undecided by FDA; Previous Story Clarified

Financial news for ALKS dated on 2012-01-04: Financial Breakfast: Morning News Summary for January 4, 2012

Financial news for ALKS dated on 2012-01-04: Alkermes Announces Positive Results From Clinical Study of ALKS 5461 for Major Depressive Disorder

Financial news for ALKS dated on 2011-12-19: Alkermes Initiates Phase 3 Clinical Study of ALKS 9070 for Treatment of Schizophrenia

Financial news for ALKS dated on 2011-12-02: Jefferies Maintains Buy Rating and \$21 PT on Alkermes

Financial news for ALKS dated on 2011-11-09: Financial Breakfast: Morning News Summary for November 9, 2011

Financial news for ALKS dated on 2011-11-09: Alkermes Announces New Long-Term Data on VIVITROL Showed Sustained Efficacy and Safety over 18 Months of Treatment

Financial news for ALKS dated on 2011-10-17: Eli Lilly Earnings Preview: Analysts Expect Rising Revenue, Falling EPS

Financial news for ALKS dated on 2011-10-12: Mad Money Lightning Round: Cramer Likes Alkermes

Financial news for ALKS dated on 2011-10-03: Alkermes Announces Initiation of Phase 2b Clinical Study of ALKS 37 for the Treatment of Opioid-Induced Constipation

Financial news for ALKS dated on 2011-09-26: Benzinga's Top Upgrades

Financial news for ALKS dated on 2011-09-26: A Peek Into The Market Before The Trading Starts

Financial news for ALKS dated on 2011-09-26: UPDATE: Jefferies Upgrades Alkermes to Buy

Financial news for ALKS dated on 2011-09-26: Jefferies Upgrades Alkermes to Buy, PT Raised to \$21

Financial news for ALKS dated on 2011-09-23: UPDATE: Goldman Sachs Raises PT on Alkermes to \$17

Financial news for ALKS dated on 2011-09-23: Goldman Sachs Raises PT on Alkermes to \$17

Financial news for ALKS dated on 2011-09-12: Merger Arbitrage Mondays - September 19, 2011

Financial news for ALKS dated on 2011-09-12: A Peek Into The Market Before The Trading Starts

Financial news for ALKS dated on 2011-09-12: Amylin Pharmaceuticals, Eli Lilly, and Alkermes Announce Analyses Find Type 2 Diabetes Patients Treated with BYDUREON(tm)

Experienced Reduction in Cardiovascular Risk Factors

Financial news for ALKS dated on 2011-09-08: Alkermes Announces Shareholder Vote in Favor of Merger with Elan Drug Technologies

Financial news for ALKS dated on 2011-08-23: UBS Upgrades Alkermes, Raises PT

Financial news for ALKS dated on 2011-08-10: Bydureon FDA Action Date Set For January 28, 2012

Financial news for ALKS dated on 2011-08-02: Options Brief: Alkermes

Financial news for ALKS dated on 2011-08-02: Jefferies Comments on Acquisition at Alkermes

Financial news for ALKS dated on 2011-08-01: Alkermes Reports Q1 EPS \$0.02 May Not be Comparable to \$(0.12) Est; Revenues \$61.9M vs \$52.67M Est

Financial news for ALKS dated on 2011-08-01: Earnings Scheduled For August 1

Financial news for ALKS dated on 2011-07-28: BYDUREON(tm) Reply Submitted to FDA

Financial news for ALKS dated on 2011-07-18: Eli Lilly & Earnings Preview: Analysts Predict Higher Earnings Over Prior Quarter

Financial news for ALKS dated on 2011-07-18: Alkermes Forecasts 2012 Pro Forma Revenues of \$460M to \$480M

Financial news for ALKS dated on 2011-07-18: Alkermes Spiking Higher on Raised Guidance

Financial news for ALKS dated on 2011-07-13: Lazard Capital Upgrades Alkermes from Neutral to Buy; Stock Jumps Over 2% on the Open

Financial news for ALKS dated on 2011-07-10: Stocks to Watch for Monday 07/11/11: Fresh 52 Week Highs and Lows

Financial news for ALKS dated on 2011-07-08: Goldman Sachs Reiterates Sell on AMLN and Neutral on ALKS

Financial news for ALKS dated on 2011-07-08: Benzinga's Top Pre-Market NASDAQ Gainers

Financial news for ALKS dated on 2011-06-30: Alkermes Announces Positive Results from Clinical Study of ALKS 9070

Financial news for ALKS dated on 2011-06-27: Pharmacoeconomic Value of Addiction Treatments, Including VIVITROL, Published in Leading Healthcare Policy Journal

Financial news for ALKS dated on 2011-06-21: News Summary for June 21, 2011

Financial news for ALKS dated on 2011-06-21: A Peek Into The Market Before The Trading Starts

Financial news for ALKS dated on 2011-06-21: Eli Lilly and Amylin Pharmaceuticals Announces BYDUREON Receives Marketing Authorization in Europe

Financial news for ALKS dated on 2011-06-01: Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer

Financial news for ALKS dated on 2011-06-01: Hapoalim Cutting Ocverage On Multitude Of Names

Financial news for ALKS dated on 2011-05-20: Calls Purchased on Alkermes, Inc.

Financial news for ALKS dated on 2011-05-19: J.P. Morgan Increases PT On ALKS To \$21

Financial news for ALKS dated on 2011-05-19: Jefferies & Company Reports on Alkermes

Financial news for ALKS dated on 2011-05-19: JP Morgan Raises PT On Alkermes To \$21

Financial news for ALKS dated on 2011-05-18: Alkermers Reports EPS of \$(0.14) vs. \$(0.14) Estimate; Revenues \$51.13M vs. \$46.73M Estimate

Financial news for ALKS dated on 2011-05-18: Earnings Scheduled For May 18 (BJ, DE, TGT, AAP, SPLS, ROST, JACK, LTD, CHS, ABMD, PETM, BRC, HOTT, ANF, ALKS, EV, NTES, CCM, SNPS)

Financial news for ALKS dated on 2011-05-16: Most Popular Stocks Right Now on 5/16/11- CNOZ, MBYL, ALKS, BAC, DANR, PRM, HPNN, LOW, BRP, PSP, WNWG

Financial news for ALKS dated on 2011-05-12: Alkermes Rises 3% Ahead Of Earnings (ALKS)

Financial news for ALKS dated on 2011-05-10: Market Upgrades on 5/10/11- HEOP, KNDL, KWK, LPX, MR, ROSE, SAM, SKS, VIA.B, ALKS, BAP, COLB, CPN, FE, GBL, GTXI

Financial news for ALKS dated on 2011-05-09: UPDATE: Hapoalim Raising Price Target On Alkermes (ALKS)

Financial news for ALKS dated on 2011-05-09: Benzinga's Volume Movers (ALKS, NUAN, BSFT, ROSE)

Financial news for ALKS dated on 2011-05-09: US Stock Futures Up; Gold Futures Surge To \$1,506.50 an ounce

Financial news for ALKS dated on 2011-05-09: Market updates: Greece, Chubu Electric, Munich Re, BARC, LLOY, CNA, TCG, ISAT, SRP, ELN, ALKS, VITA, BHP, HBC, LMI

Financial news for ALKS dated on 2011-04-16: CEOWORLD Daily Business Roundup- JNJ, CHK, AMD, T, AXP, AAPL, INTC, JPM, GOOG, LLY, CSCO...

Financial news for ALKS dated on 2011-04-15: Top Percentage Gainers and Losers as of 10am 4/15/11 (AGO, OPXA, MBI, AMLN, ABMD, CTCT, CRUS, GGC, OTIV, SFG, BAC, LLY, ALKS)

Financial news for ALKS dated on 2011-04-15: BYDUREON Recommended For Approval In Europe (LLY, ALKS)

Financial news for ALKS dated on 2011-04-15: Eli Lilly, Amylin Pharmaceuticals, and Alkermes Announce BYDUREON Recommended for Approval in Europe

Financial news for ALKS dated on 2011-04-15: Alkermes' BYDUREON Receives Approval In Europe (ALKS)

Financial news for ALKS dated on 2011-03-03: Amylin Pharmaceuticals, Eli Lilly and Alkermes Announce Top-line Results from DURATION-6 Study

Financial news for ALKS dated on 2011-03-03: Trading Halted: Alkermes, News Pending

Financial news for ALKS dated on 2011-02-15: Alkermes Announces Positive Preliminary Results from Phase 2 Study of ALKS 37

Financial news for ALKS dated on 2011-02-04: Options Brief: Alkermes (ALKS)

Financial news for ALKS dated on 2011-02-04: Hapoalim Reiterates Buy on Alkermes (ALKS)

Financial news for ALKS dated on 2011-02-03: Alkermes Reports Third Quarter Fiscal 2011 Financial Results: Loss of \$0.12 Per Share

Financial news for ALKS dated on 2011-01-31: Earnings Preview: Alkermes - Analyst Blog

Financial news for ALKS dated on 2011-01-31: Earnings Preview: Alkermes - Analyst Blog

Financial news for ALKS dated on 2011-01-27: Cost Control Helps Amylin Cut Loss - Analyst Blog

Financial news for ALKS dated on 2011-01-27: Cost Control Helps Amylin Cut Loss - Analyst Blog

Financial news for ALKS dated on 2011-01-20: MannKind in Jeopardy - Analyst Blog

Financial news for ALKS dated on 2011-01-20: MannKind in Jeopardy - Analyst Blog

Financial news for ALKS dated on 2011-01-18: Alkermes Elects Wendy L. Dixon to Board of Directors

Financial news for ALKS dated on 2011-01-11: Long ALKS At \$12.68

Financial news for ALKS dated on 2011-01-07: Top 4 Small-Cap Stocks In The Drug Delivery Industry With The Highest Cash (ALKS, PETS, KV-A, MTXX)

Financial news for ALKS dated on 2010-12-23: Label Expansion Sought for Byetta - Analyst Blog

Financial news for ALKS dated on 2010-12-23: Label Expansion Sought for Byetta - Analyst Blog

Financial news for ALKS dated on 2010-12-21: Rolling BLA for AMLN's Metreleptin - Analyst Blog

Financial news for ALKS dated on 2010-12-21: Rolling BLA for AMLN's Metreleptin - Analyst Blog

Financial news for ALKS dated on 2010-12-09: Good News for Alkermes' Pipeline - Analyst Blog

Financial news for ALKS dated on 2010-12-09: Good News for Alkermes' Pipeline - Analyst Blog

Financial news for ALKS dated on 2010-11-24: Amylin Stays Neutral - Analyst Blog

Financial news for ALKS dated on 2010-11-24: Amylin Stays Neutral - Analyst Blog

Financial news for ALKS dated on 2010-11-12: Zacks Analyst Blog Highlights: Lions Gate Entertainment, Amylin Pharmaceuticals, Amylin Pharmaceuticals, Eli Lilly, Alkermes and Novo Nordisk - Press Releases

Financial news for ALKS dated on 2010-11-08: Revenues Rise at ALKS, View Lowered - Analyst Blog

Financial news for ALKS dated on 2010-11-05: Hapoalim Securities Has \$16 Target On Alkermes (ALKS)

Financial news for ALKS dated on 2010-11-04: Alkermes Reports Second Quarter Fiscal 2011 Financial Results: Loss Per Share of \$0.08

Financial news for ALKS dated on 2010-11-02: Top 4 Stocks In The Drug Delivery Industry With The Highest Cash (HSP, ELN, NKTR, ALKS)

Financial news for ALKS dated on 2010-10-21: Hapoalim Securities Defends Alkermes (ALKS)

Financial news for ALKS dated on 2010-10-20: Benzinga's Top Pre-Market NASDAQ Losers (AMLN, ALKS, FSII, CREE)

Financial news for ALKS dated on 2010-10-20: Benzinga's Top Pre-Market NASDAQ Losers (AMLN, ALKS, FSII, CREE)

Financial news for ALKS dated on 2010-10-20: Benzinga's Top Pre-Market NASDAQ Losers (AMLN, ALKS, FSII, CREE)

Financial news for ALKS dated on 2010-10-20: Benzinga's Top Pre-Market NASDAQ Losers (AMLN, ALKS, FSII, CREE)

Financial news for ALKS dated on 2010-10-20: Amylin Pharmaceuticals Crushed In Pre-Market (AMLN)

Financial news for ALKS dated on 2010-10-18: FDA Nod for Alkermes' Vivitrol - Analyst Blog

Financial news for ALKS dated on 2010-10-14: Top 4 Stocks In The Drug Delivery Industry With The Highest Cash (ELN, HSP, NKTR, ALKS)

Financial news for ALKS dated on 2010-10-13: Jefferies & Company Projects Alkermes Sales of \$40M

Financial news for ALKS dated on 2010-10-12: Benzinga's After Hours Gainers (INTC, ALKS, CSCO, CSX, ODP)

Financial news for ALKS dated on 2010-10-04: Readers Pick Drug Approval Winners & Losers

Financial news for ALKS dated on 2010-10-01: Benzinga's Top Pre-Market NASDAQ Gainers (GYMB, CCME, ALKS, ARMH)

Financial news for ALKS dated on 2010-09-30: PRX, ALKS, Initiated At Buy

Financial news for ALKS dated on 2010-09-17: Thumbs Up for ALKS Drug - Analyst Blog

Financial news for ALKS dated on 2010-09-17: Benzinga's Volume Movers (UTHR, GSM, ALKS, ORCL)

Financial news for ALKS dated on 2010-09-17: Hapoalim Likes Alkermes After FDA Panel Recommendation (ALKS)

Financial news for ALKS dated on 2010-09-17: Benzinga's Top Pre-Market NASDAQ Gainers (CRXL, ALKS, CCME, RIMM)

Financial news for ALKS dated on 2010-08-31: 21 Drugs Facing FDA Approval Decisions

Financial news for ALKS dated on 2010-08-18: Mad Money Lightning Round OT (SOLR, ZION, ALKS)

Financial news for ALKS dated on 2010-08-09: Revenues Dip at Alkermes - Analyst Blog

Financial news for ALKS dated on 2010-08-09: Stocks Hitting 52-Week Highs (ALKS, BIDU, CHRW, ENDP)

Financial news for ALKS dated on 2010-08-06: Hapoalim Rates Alkermes "Buy"

Financial news for ALKS dated on 2010-08-05: Alkermes Reports First Quarter Fiscal 2011 Financial Results

Financial news for ALKS dated on 2010-08-03: Zacks #5 Rank Additions for Tuesday - Tale of the Tape

Financial news for ALKS dated on 2010-06-28: Low Yields, Consumer Confidence, Income Impact 06-28-2010

Financial news for ALKS dated on 2010-06-28: Four Sectors Worth Watching 06-28-2010

Financial news for ALKS dated on 2010-06-28: Downside Purchased on Alkermes Inc. (ALKS)

Financial news for ALKS dated on 2010-06-25: Top 4 Stocks In The Drug Delivery Industry With The Highest Gross Margin (BVF, ALKS, MTXX, NKTR)

Financial news for ALKS dated on 2010-06-18: Benzinga's Volume Movers (ZUMZ, AMLN, ALKS, HTWR)

Financial news for ALKS dated on 2010-06-18: Calls Purchased on Alkermes (ALKS)

Financial news for ALKS dated on 2010-05-14: Market Round-Up (GOOG, ALKS)

Financial news for ALKS dated on 2010-03-21: How Will Obama-Care Play Into The Markets And ETFs?

Financial news for ALKS dated on 2010-03-15: Stocks That Created New 52-Week Highs (AIRT, ALKS, ALLT, ATEC, AMIC)

Financial news for ALKS dated on 2010-03-15: Benzinga's Volume Movers (AMLN, ALKS, FNSR, PEGA, BIDU)

Financial news for ALKS dated on 2010-03-15: US Stock Futures Fall On Concerns Over Chinese Monetary Policy

Financial news for ALKS dated on 2010-03-15: Benzinga's News Roundup (PEP, ALKS, MRK)

Financial news for ALKS dated on 2010-03-15: Benzinga's Top Pre-Market Gainers (PVH, AMLN, CHRD, ISIS, NVAX)

Financial news for ALKS dated on 2010-03-09: Benzinga's Top Pre-Market Gainers (CELM, FEED, CXDC, CERS, ALKS)

Financial news for ALKS dated on 2010-03-08: AMLN Is Waiting For A Decision On Byetta

Financial news for ALKS dated on 2010-02-05: Alkermes, Inc. (ALKS) Third-Quarter Review

Financial news for ALKS dated on 2010-02-05: Alkermes (ALKS) Raised to Buy On Consta's Record Sales

Financial news for ALKS dated on 2009-11-18: Volume Talks: Hot Stocks on Heavy Volume & Detailed Buy Write Option Trade